WaveMan
WaveMan · Company
RVPH · Reviva Pharmaceuticals Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RVPH Reviva Pharmaceuticals (RVPH) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001742927
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Reviva Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for REVIVA PHARMACEUTICALS HOLDINGS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Patel Purav
Director
BUY
2022-11-21 SECtraded 2022-11-18
3,000
$14.1K
-99.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 6.9% of the 43,547 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Director Patel Purav bought about $14.1K of RVPH on Nov 18, 2022.
Narayan Prabhu
Chief Financial Officer
BUY
2022-10-03 SECtraded 2022-09-30
50,000
$83.0K
-98.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 30, 2022.
  • The trade is 50.0% of the 100,000 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Chief Financial Officer Narayan Prabhu bought about $83.0K of RVPH on Sep 30, 2022, the largest insider purchase at the company on our record.
Narayan Prabhu
Chief Financial Officer
BUY
2022-06-30 SEC
50,000
$60.5K
-98.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 50,000 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Chief Financial Officer Narayan Prabhu bought about $60.5K of RVPH on Jun 30, 2022, the largest insider purchase at the company on our record.
3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
3.4% of the float short (float per yahoo 2026-10-26) · 12.1 days to cover · settled 2026-09-30
below 60% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch RVPH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-94.9%12M
-96%-42%+11%+65%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RVPH: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in RVPH

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RVPH planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RVPH financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.01x
current debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-120.09x
TTM operating cash flow over current debt only, 2026-06-30
Return on equity
-176.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-79.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-182.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
-$13.9M
market value at close 2026-10-23 on 2026-08-13 shares, plus current debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$20.2M-$30.8M-$39.5M-$28.2M
Net income-$19.9M-$29.9M-$39.3M-$28.3M
Operating cash flow-$24.6M-$33.5M-$28.3M-$19.0M
Cash$14.4M$13.5M$23.4M$18.5M
SEC XBRL, fiscal years, as known on 2026-10-27

RVPH Stock Sonar score 3/7 axes

Find similar shapesCompare

RVPH ranks highest on risk and compliance (66th percentile) and financial health (42nd), and lowest on profitability (20th), among Pharma & Biotech peers.

Profitability
20
Inputs
  • Return on equity-176.6% · 19 pct, sector of 545
  • Return on assets-79.5% · 30 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-182.6% · 12 pct, sector of 576
Financial health
42
Inputs
  • Debt to equity0.01x · 77 pct, sector of 352
  • Cash flow to debt-120.09x · 7 pct, sector of 371
Risk and compliance
66
Inputs
  • Short interest, % of float+3.4% · 66 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Growth, Insider conviction, Institutional and government, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies